Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Rituximab and Belimumab in Resistant Juvenile Sjogren's Syndrome
NCT06410833Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of belimumab, rituximab in Sjogren's syndrome, sponsored by Peking Union Medical College Hospital. Started Mar 2024; status: recruiting.
02
Drugs
belimumabrituximab
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT06410833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06410833.